European Commission Authorizes Gilead's Marketing of Remdesivir for Covid-19 Treatment
July 03 2020 - 9:14AM
Dow Jones News
By Jessica Sier
Gilead Sciences Inc.'s remdesivir has been granted marketing
authorization by the European Commission for the treatment of
coronavirus, the company said Friday.
The authorization allows the antiviral drug to be used in the
European bloc in the treatment of patients with Covid-19 aged 12
and older who have pneumonia and require supplemental oxygen.
"The conditional marketing authorization was granted in the
interest of public health due to the Covid-19 pandemic and was
based on a rolling review of supporting data that began in April
2020," Gilead said.
The conditional marketing authorization is initially valid for
one year, but can be extended.
In the U.S., remdesivir is authorized for use in emergencies for
patients with severe coronavirus.
Write to Jessica Sier at jessica.sier@wsj.com
(END) Dow Jones Newswires
July 03, 2020 08:59 ET (12:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024